Collagen derived serum markers in carcinoma of the prostate.
暂无分享,去创建一个
[1] J. Risteli,et al. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. , 1993, Clinical chemistry.
[2] J. Oesterling,et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.
[3] T. Tammela,et al. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. , 1993, European journal of cancer.
[4] E. Cooper,et al. Tumor markers in prostate cancer , 1992, Cancer.
[5] H. Scher,et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. , 1992, The Journal of urology.
[6] Y. Arai,et al. Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? , 1992, The Prostate.
[7] J. Oesterling,et al. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.
[8] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[9] C. Christiansen,et al. The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones. , 1991, Metabolism: clinical and experimental.
[10] R. Sylvester,et al. Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic Cancer , 1990, Cancer.
[11] P. Robinson,et al. Some Limitations of the Radioisotope Bone Scan in Patients With Metastatic Prostatic Cancer , 1990, Cancer.
[12] J. Risteli,et al. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. , 1990, Clinical chemistry.
[13] T. Stamey,et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. , 1989, The Journal of urology.
[14] R. Sylvester,et al. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. , 1989, The Journal of urology.
[15] M. Caleffi,et al. Osteocalcin: a potential marker of metastatic bone disease and response to treatment. , 1988, European journal of cancer & clinical oncology.
[16] J. Risteli,et al. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. , 1988, Clinical chemistry.
[17] J. Grob,et al. Quantitative bone scintigraphy: usefulness in the survey of patients treated for bone metastasis of prostatic cancer. , 1988, European urology.
[18] Sogani Pc,et al. Treatment of advanced prostatic cancer. , 1987 .
[19] S. Suciu,et al. Do bone scans predict prognosis in prostatic cancer? A report of the EORTC protocol 30762. , 1984, British journal of urology.
[20] M. Soloway,et al. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. , 1983, The Journal of urology.
[21] M. Menon,et al. Tumor Markers in Prostatic Cancer , 1983 .
[22] H. Pendergrass,et al. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. , 1976, Radiology.